Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2025-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于深圳华大基因股份有限公司2022年限制性股票激励计划之授予价格调整、归属条件成就及部分限制性股票作废事项的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 restricted stock incentive plan of Shenzhen BGI Genomics Co., Ltd. It discusses the adjustment of grant prices, achievement of vesting conditions, and cancellation of some restricted stocks. The document references legal and regulatory frameworks, approvals by the board and supervisory committees, and compliance with relevant laws and regulations. It is a standalone legal opinion on specific corporate actions related to stock incentives, not a full annual or interim financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on legal compliance and authorization of stock incentive plan adjustments and cancellations. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit or legal compliance reports related to corporate governance and regulatory matters, excluding full annual reports or earnings releases.
2025-04-25 Chinese
关于2025年度公司及子公司向银行等金融机构申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the company's and its subsidiaries' application for a comprehensive credit facility from banks and financial institutions for the year 2025. It details the credit limits requested, the purpose of the credit, and the approval process including board and shareholder meetings. The document does not contain financial statements or detailed financial performance data but is a formal disclosure of financing plans and credit applications. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 1771 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is CAP with high confidence.
2025-04-25 Chinese
2024年度营业收入扣除情况专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度营业收入扣除情况专项说明" which translates to a "Special Explanation on the Deduction of Operating Revenue for the Year 2024" for Shenzhen BGI Genomics Co., Ltd. It includes an audit opinion from Ernst & Young Hua Ming dated April 24, 2025, referencing the audit of the 2024 financial statements. The document contains detailed tables showing revenue deductions and explanations, and it is explicitly stated that this special explanation is prepared for use in the 2024 annual report disclosure. The document is 2116 characters long, which is relatively short and focused on a specific aspect of the financials (revenue deductions) rather than a full annual report. It is a standalone audit-related explanation document, not the full annual report itself. It is not a mere announcement or certification but contains substantive audited financial data related to revenue deductions. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report with applied accounting principles and audit results, distinct from the full annual report (10-K).
2025-04-25 Chinese
监事会关于2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期归属名单的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Supervisory Board of Shenzhen BGI Genomics Co., Ltd. regarding the verification of the vesting list for the second vesting period of the first grant and the first vesting period of the reserved grant under the 2022 restricted stock incentive plan. It discusses compliance with relevant laws, regulations, and company rules, and confirms the eligibility and vesting conditions of the incentive recipients. This type of document is related to remuneration and stock incentive plans for executives and key personnel, which falls under Remuneration Information filings. The document is not a full annual report, audit report, or financial statement, but a specific report on stock incentive vesting verification, fitting the Remuneration Information category.
2025-04-25 Chinese
公司章程（2025年4月）
Governance Information Classification · 100% confidence The document is titled "深圳华大基因股份有限公司章程" which translates to "Articles of Association of Shenzhen BGI Genomics Co., Ltd." It contains detailed company governance rules, including chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution and audit, notices and announcements, mergers, capital changes, dissolution and liquidation, and amendments to the articles. The content is a comprehensive governance document outlining the company's internal rules, board structure, shareholder rights, and management responsibilities. There is no indication that this is an annual report, audit report, earnings release, or any other financial report. Instead, it is a governance document specifying the company's constitution and operational rules. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-04-25 Chinese
关于2024年度拟不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding the company's 2024 profit distribution plan, specifically stating that no cash dividends will be distributed for the year 2024. It includes details about the board and supervisory committee meetings where the proposal was approved, audit opinions, and explanations about the company's financial status and reasons for not distributing profits. The document is relatively short (3820 characters) and focuses on the profit distribution plan rather than presenting full financial statements or comprehensive financial performance data. It does not contain detailed financial reports or actual financial statements but rather a specific announcement about dividend policy and profit distribution decisions. Therefore, it fits best into the category of Notice of Dividend Amount (DIV), as it announces the dividend decision and related details for shareholders.
2025-04-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.